It was recommended by consensus that a short course of dual therapy with OAC and an antiplatelet agent (preferably P2Y12) should be considered as a preferred antithrombotic strategy in the therapeutic process of patients with both ACS and AF (9, 33), and OAC should be applied in the long term of the patients' antithrombotic procedure (9). Here, P2RY12 is linked to atrial fibrillation.